AstraZeneca Target Cut to GBP120 From GBP140 by Intron Health
AstraZeneca Cut to Hold From Buy by Intron Health
BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024
CSPC Pharma rose more than 6% in early trading. The group signed an exclusive licensing agreement with AstraZeneca.
CSPC Pharma (01093) rose 5.51% in early trading, now trading at 7.09 Hong Kong dollars, with a turnover of 0.585 billion Hong Kong dollars. CSPC Pharma has issued an announcement.
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Goldman Sachs: Buy rating on CSPC Pharma with a target price of HK$10.03.
Goldman Sachs released a research report stating a 'buy' rating for CSPC Pharma (01093), with a target price of 10.03 Hong Kong dollars. The company aims to complete 1-2 BD trades within 2024, and emphasizes continuous review of product lines, strengthening business expansion efforts. The bank expects more trades to occur in the future. It was mentioned that CSPC Pharma plans to authorize YS2302018 (a small molecule inhibitor of lipoprotein (a) in the preclinical stage) and any products containing YS2302018 global rights. The company's first collaboration with AstraZeneca is seen by the bank as a global expansion for the company.
Arcus a New Overweight at Wells Fargo on Potential of Casdatifan in Kidney Cancer
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
AstraZeneca Deal Has Positive Read for Silence Therapeutics, Says Morgan Stanley
Another old pharmaceutical company has successfully transformed through innovation.
Intensive product BD, heavyweight personnel appointments, 5 billion repurchase plan, cspc pharma's stock price surged more than 60% in three weeks.
AstraZeneca's Phase III Trial of Treatment for Asthma Meets Its Primary Endpoint
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $95
CSPC Pharmaceutical Set to Benefit From Exclusive Licensing Agreement With AstraZeneca -- Market Talk
Goldman Sachs Sticks to Its Buy Rating for AstraZeneca (AZN)
HK stocks are in a special situation | CSPC Pharma (01093) opened more than 9% higher, reaching an exclusive licensing agreement with astrazeneca for YS2302018.
CSPC Pharma (01093) opened more than 9% higher, up 9.55% as of the time of publication, at 7.8 Hong Kong dollars, with a turnover of 0.114 billion Hong Kong dollars.
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge
European Equities Close Mostly Higher in Monday Trading; BP Scraps Plan to Cut Oil, Gas Output by 2030
AstraZeneca, CSPC Deal Shows Lp(a) Space Remains Hot, Says BMO Capital
Precidian to List First ADRhedged Securities in the U.S. on Cboe, Providing Exposure to Individual International Companies With an Embedded Currency Hedge